IntraBio Accelerates CACNA1A Trial Enrollment, Aims for October Completion
Event summary
- IntraBio's Phase III trial (IB1001-304) for levacetylleucine in CACNA1A-related disorders is enrolling, with over-enrollment expected by October 2026.
- The trial is the first pivotal study for CACNA1A-related disorders, using a design similar to IntraBio's approved NPC and ongoing A-T trials.
- CACNA1A-related disorders affect ~30,000 in the U.S. and 690,000 globally, with no currently approved therapies.
- The trial is multinational, spanning sites in the U.S., Europe, and the U.K., with a 6-month completion timeline.
The big picture
IntraBio's accelerated enrollment in the CACNA1A trial underscores its strategy of repurposing levacetylleucine across rare neurological diseases. The company is positioning itself as a leader in calcium-channel-related disorders, following its success in NPC and ongoing A-T trial. The trial's multinational scope reflects IntraBio's global ambitions, though execution risks remain due to the rarity of the condition.
What we're watching
- Regulatory Momentum
- Whether IntraBio can leverage the Phase III trial's success to secure accelerated approvals, following its positive A-T trial results.
- Execution Risk
- The pace at which IntraBio can maintain over-enrollment and complete the trial by October 2026, given the rarity of CACNA1A-related disorders.
- Market Expansion
- How IntraBio will position levacetylleucine as a potential multi-indication therapy, given its existing approvals for NPC and ongoing A-T trial.